Pharmacogenetics of Proton Pump Inhibitors: A Systematic Review

17 pertinent citations in our profession examination (Table 1); the point of indicant for each was categorized using the appraisal fleck discussed above. The citations consisted of four prospective, randomized, controlled studies (level I); one prospective, nonrandomized, controlled immersion (level II-1); 3 prospective, nonrandomized, uncontrolled (cohort) studies[28, 37, 38] (level II-2); one retrospective composition (level III); one case account (level III); and sevener studies with deputy end points (e.g., intragastric pH, proportion of time above pH 4)[41-47] (below storey III).Degree I Indicant: Studies with at Least One Properly Randomized, Controlled Run
Four randomized, controlled studies addressed the role of CYP2C19 pleomorphism in patients who received PPIs to eradicate H. pylori .
Triad prospective, randomized studies with omeprazole and Aciphex showed that H. pylori eradication therapy is freelancer of CYP2C19 genetic pleomorphism. However, a try with omeprazole and lansoprazole demonstrated the inverse phenomenon.
One of the studies involved 174 Altaic language adults (89% men, mean ± SD age 49.8 ± 8.2 yrs) with peptic ulcer disease and positive degree cultures of H. pylori from endoscopic biopsy. Musing subjects were randomized to dual therapy with amoxicillin 1500 mg/day and either omeprazole 40 mg/day or Aciphex 20 mg/day (duration not specified).
Between 1 and 2 months after the end of eradication therapy, endoscopy and a [13C]-urea breathing time test were performed to assess H. pylori position.
This is a part of article Pharmacogenetics of Proton Pump Inhibitors: A Systematic Review Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog